Stable pool titers across 6 representative programs:Fc-fusion, nanobody fusion, 4-chain bispecific, lipoprotein, and two mAbs. All ≥7 g/L.

Product
Pool predicts clone. Every molecule. Every time.
How GOLDILOCKS Works
GOLDILOCKS™ is the only transposase platform engineered to eliminate every failure mode of random integration at the source – not to work around them.
15-20 independent integration sites, one copy per site. Eliminates the concatemer-induced silencing that drives expression decline in random-integration cell lines.
The entire expression cassette integrates as a single unit – regulatory elements stay linked to their ORFs. No rearrangements, no orphaned promoters, no broken stoichiometry.
Integration is biased toward transcriptionally active loci. Your gene lands where the cell is already willing to express – not in heterochromatic silencing zones.
Clones average 50% above pool titer with tight distribution. Screen fewer clones.
Universal pLG™ construct handles mAbs, bispecifics, ADCs, Fc-fusions, nanobody fusions, enzymes, cytokines. No per-molecule optimization. Up to 100-200 kb cargo.
>95% expression retained over 120+ generations without selective pressure.
Proof points
Stable pool titers across 6 representative programs:Fc-fusion, nanobody fusion, 4-chain bispecific, lipoprotein, and two mAbs. All ≥7 g/L.

Pool titers reliably predict clone performance, reducing the number of clones that need to be screened.

Expression remains stable through extended culture without ongoing selection pressure.

How to Access GOLDILOCKS
Test the platform before committing to a path:
Ideal for: platform evaluation, early biology readouts, molecule de-risking.
For groups with in-house CLD infrastructure
Ideal for: labs running 5+ CLD programs/year, platform CDMOs, scaled biotech R&D.
For groups with in-house CLD infrastructure
Ideal for: most biotech programs; gene to clone with no in-house CLD burden.
SUPERCELL™ is a next-generation CHO-K1 host cell line purpose-built for difficult-to-express proteins. Derived from the original Puck laboratory CHO-K1 lineage, SUPERCELL™ delivers superior expression of challenging molecule formats—including scFvs, bispecifics, and non-mAb therapeutics—with higher yields and improved product quality compared to standard CHO-K1 platforms.